4 reasons to like Wells Fargo, plus Eli Lilly's latest launch and Boeing ramps up

Major financial news saw Wells Fargo shares gain on an upbeat mid-quarter update from its CFO, who noted 'green shoots' post-asset cap lift, significant share repurchases, and an unchanged net interest income outlook, signaling renewed growth potential and confidence. Eli Lilly also rallied after a key reversal from the Institute for Clinical Economic Review deemed GLP-1 obesity drugs cost-effective, a critical step for securing broader payer coverage, while the company simultaneously launched TuneLab, an AI platform aimed at accelerating early-stage drug discovery. Meanwhile, Boeing reported its strongest August aircraft deliveries since 2018, with 57 units, though investor focus remains on the potential lifting of the 737 MAX production cap.

Analysis

Wells Fargo (WFC) stock gained approximately 2% following a constructive mid-quarter update from its CFO, which outlined several positive catalysts. The lifting of the firm's $1.95 trillion asset cap is reportedly enabling renewed offensive strategies, with management citing "really good green shoots" in attracting deposits and growing its wealth and asset management businesses. Confidence in the bank's outlook is further underscored by its most aggressive single-quarter share repurchase of the year, totaling $5.5 billion. The decision to maintain its net interest income (NII) guidance was viewed as a stabilizing signal after a previous cut in July, while the credit card division was identified as a "huge opportunity" for meaningful bottom-line contributions over the next few years. Analyst reactions were positive, with Piper Sandler raising its price target to $88, although TD Cowen maintained a hold rating, acknowledging progress but expecting a more gradual revenue recovery.

Eli Lilly (LLY) shares rallied on two key developments. Firstly, a draft report from the Institute for Clinical Economic Review reversed its prior stance, now deeming GLP-1 obesity drugs cost-effective, a critical step toward securing broader employer and payer coverage and unlocking further growth. Secondly, Lilly launched TuneLab, a proprietary AI platform designed to accelerate early-stage drug discovery. This platform, part of the broader Catalyze360 initiative and leveraging Nvidia technology, will be offered at no cost to biotech firms in exchange for their research data, employing a federated learning model to ensure data privacy. While not an immediate financial needle-mover, this move represents a significant strategic investment in long-term innovation to sustain growth beyond current patent cycles.

Boeing (BA) reported its best August aircraft deliveries since 2018, delivering 57 aircraft and booking 26 gross orders with no cancellations. Despite this operational strength, the stock saw a muted reaction, indicating that investor focus remains squarely on the potential lifting of the 737 MAX monthly production cap, which is the more significant catalyst for future financial performance. An update on this matter is anticipated at an upcoming Morgan Stanley conference.

Key Decisions for Investors

• Investors in Wells Fargo should view the aggressive $5.5 billion share repurchase and commentary on growth post-asset cap lift as strong signals of management confidence, though they should monitor upcoming quarters to confirm that the 'green shoots' translate into material revenue growth.
• The favorable ICER report on GLP-1 cost-effectiveness is a significant de-risking event for Eli Lilly's obesity drug franchise, potentially accelerating sales by improving insurance coverage, making near-term prescription volume and payer announcements key metrics to watch.
• For Boeing, the strong August delivery numbers are a positive operational data point, but investor focus should remain fixed on management's upcoming commentary regarding the lifting of the 737 MAX production cap, as this is the primary catalyst for unlocking significant future revenue.
• Eli Lilly's launch of the TuneLab AI platform, while not an immediate earnings driver, represents a strategic investment in R&D efficiency that could enhance its long-term competitive advantage, warranting attention from investors focused on innovation pipelines.